From $3.6M to Possible $150M: Diginex’s Resulticks Deal Could Transform Revenue — If It Closes

Diginex unveils Risk-to-Remedy compliance platform, but shares hit $1, down 36% in 30 days, as $1.5B Resulticks deal faces June 12 deadline and Nasdaq delisting risk.

Diginex rolled out an integrated supply chain compliance tool on June 4 that addresses a market expected to nearly triple from $3.8 billion to $9.6 billion over the next decade. Yet investors barely blinked. The stock closed Friday at exactly $1.00, down nearly 4% on the day and roughly 36% over the past 30 days — a selloff that has pushed the relative strength index to a deeply oversold 29.6 and annualized volatility past 155%.

The new platform, called Risk-to-Remedy, bundles the company’s LUMEN risk assessment tool with APPRISE, a worker engagement module, and layers in expertise from The Remedy Project, which Diginex acquired earlier this year. The timing is intentional: tightening human-rights due diligence laws in Europe, the UK, Australia, Canada and Germany are forcing companies to document supply chain risks more rigorously. But the product news has been completely overshadowed by a much bigger event — the proposed $1.5 billion acquisition of Resulticks Global Companies.

That deal, originally signed on April 16 with a target closing date of May 29, has already been pushed back once. Diginex extended the deadline to June 12, citing outstanding closing conditions. The company stressed there is no guarantee the transaction will be completed. If it does close, Resulticks would immediately transform Diginex from a niche ESG software provider into a larger platform player, adding roughly $150 million in annual revenue and between $46 million and $50 million in EBITDA. In contrast, Diginex’s own trailing twelve-month revenue stands at just $3.6 million — though that represents a 203% year-over-year jump from a tiny base.

The market cap hovers around $30 million, making the all-stock Resulticks deal a bet of staggering proportions. To put it in context, Diginex has completed more than $100 million in acquisitions since its Nasdaq listing in January 2025, including Matter DK ApS for $13 million, The Remedy Project for $7.6 million, and Plan A for $80 million. The Resulticks deal alone would dwarf all of those combined.

Meanwhile, the Nasdaq compliance clock is ticking. Diginex received a formal warning in March after its shares traded below $1 for 30 consecutive sessions. Management responded with a 1-for-8 reverse split in late April, but the stock has since drifted back to the critical threshold. With the stock bumping $1 again, another grace period could be triggered — but only if the company can stabilize its share price.

Diginex’s data subsidiary Matter offers a glimmer of operational progress. It manages assets worth $20 trillion for institutional clients and recently boosted its carbon data extraction automation rate from 25% to 80%, allowing it to release sustainability data for more than 1,000 companies faster than before. Yet such advancements do little to calm investors who are fixated on the Resulticks deadline.

The next few days will determine whether Diginex can pull off the transformative deal or faces a fresh wave of skepticism. A successful close would instantly multiply revenues by a factor of 40 and reshape investor perception. Another delay would likely deepen the selloff and raise questions about the company’s ability to execute on its stated ambitions.